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Objective: Evaluating the effects of implementing an antidepressant treatment strategy in depressed
myocardial infarction (MI)-patients on long-term cardiovascular outcomes and all-cause mortality.
Methods: MI-patients were evaluated for the presence of a diagnosis of post-MI depression at 3, 6, 9 and
12 months after hospitalization for MI. A total of 331 depressed MI-patients were randomized to interven-
tion or care-as-usual (CAU). Patients randomized to the intervention were offered several antidepressant
treatment options including pharmacological and non-pharmacological therapy. Patients randomized to
CAU were not given feedback about their depression status. All patients were free to seek depression
treatment outside the study, which was monitored. The primary outcome was a combined endpoint of
cardiovascular events and cardiac mortality between randomization and 8 years later. All-cause mortality
was evaluated as secondary endpoint.
Results: The intervention did not reduce the risk of the primary outcome (HR: 0.97 (95% CI: 0.67–1.40) n=330)
or all-cause mortality (HR: 0.74 (95% CI: 0.41–1.33) n=330). Regardless of randomization status, patients who
received depression treatment (n=168) had reduced all-cause mortality rates compared to those who did not
receive treatment (n=143, HR: 0.52 (95% CI: 0.28–0.97)).
Conclusion: Implementing an antidepressant treatment strategy did not reduce the risk of cardiovascular
morbidity and mortality compared to usual care. Receiving depression treatment increased survival. It remains
unclear whether this represents a direct treatment effect or is due to unmeasured factors that relate to both
receiving depression treatment and mortality, such as patients' intrinsic motivation to care for their health.© 2012 Elsevier Inc. Open access under the Elsevier OA license.Introduction
Depression after myocardial infarction (MI) is associated with
worse cardiovascular outcomes [1]. Unfortunately, large-scale ran-
domized controlled trials (RCTs) in depressed cardiac patients found
treatment for depression not to affect cardiac prognosis [2–4]. In the
Enhancing Recovery in Coronary Heart Disease trial (ENRICHD),
6 months of cognitive behavioral therapy (CBT) in 2481 MI-patients
with depression or low social support had no impact on cardiac mor-
bidity and mortality [2]. In the Sertraline Antidepressant Heart Attack
Randomized Trial (SADHART), 6 months of sertraline treatment had
no impact on 8-year survival rates in 361 depressed acute coronary
syndrome patients [4]..
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Depression Intervention Trial (MIND-IT, [5]). In this RCT, the implemen-
tation of an active antidepressant treatment strategy in depressed MI
patients had no effect on depression and cardiovascular outcomes till
18 months post-MI [6]. However, potential beneﬁcial effects on cardio-
vascular prognosis may only appear after a longer follow-up time. The
reason for this is that a substantial part of the prognostic impact of
post-MI depression can be explained by mechanisms that act on long-
term cardiac prognosis, such as physical inactivity [7], difﬁculties with
smoking cessation [8], and non-adherence to cardiac aftercare regimens
[9]. Furthermore, depression has been shown to predict poor health
outcomes and mortality even after 10 years of follow-up [10–12].
Therefore, in the present article we evaluated whether MIND-IT's
intervention (i.e. implementing an active antidepressant treatment
strategy) is associated with reduced cardiovascular morbidity and
mortality rates till 8 years after treatment initiation. After this, we did
two secondary analyses, comparing cardiovascular outcomes between
(1) patients who responded to antidepressants and those who did
not, and (2) patients who actually received treatment for depression
and those who did not, regardless of randomization.
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Study design and participants
MIND-IT was a multicenter RCT with the goal to determine the ef-
fectiveness of implementing an antidepressant treatment strategy
compared to care as usual (CAU). Details of the study have been de-
scribed before [5,6]. Brieﬂy, patients consecutively admitted for MI
to one of eleven hospitals in the Netherlands between September
1999 and November 2002 were assessed for eligibility. Eligible pa-
tients met at least two of the following criteria: (1) chest pain for at
least 20 min, (2) typical electrocardiographical changes, and (3) a
documented increase in cardiac enzyme levels. Patients were
excluded if they were unable to communicate, were not available
for follow-up, had another somatic disease likely to inﬂuence short-
term survival, already received treatment for depression or were par-
ticipating in another clinical trial.
Eligible MI-patients were screened with the Beck Depression In-
ventory (BDI) [13] at hospitalization, and 3, 6, 9 and 12 months
after the MI. Those scoring ≥10 were administered the Composite In-
ternational Diagnostic Interview (CIDI) version 2.1 [14] to assess the
presence of an International Classiﬁcation of Diseases (ICD)-10 diagno-
sis of a depressive episode after the MI [15]. CIDI interviews were not
administered earlier than 3 months after the MI, to allow for natural
recovery of depressive symptoms just after the MI. Patients diagnosed
with a post-MI depressive episode were randomized.
The institutional review board of each participating hospital ap-
proved the protocol and each participant signed informed consent.
All participating patients were informed that they were free to seek
help for mood problems outside the study protocol.
Intervention
Feedback about the depression status was given only to patients in
the intervention arm and not to patients or their practitioners in the
CAU arm (i.e. a Zelen design [16]). Patients in the intervention arm
were offered several treatment options. The ﬁrst option was to partic-
ipate in a double-blind placebo-controlled trial on the efﬁcacy of
mirtazapine. In case of no sufﬁcient treatment response after eight
weeks, deﬁned as at least 50% reduction in the Hamilton Depression
Rating Scale (HDRS [17]) score or an HDRS-score of less than 10 at
8 weeks, patients in both arms were offered open treatment with
citalopram. The second option was open treatment with citalopram.
The third option was ‘tailored treatment’, which was at the discretion
of the psychiatrist. For all patients in the intervention arm, monthly
visits to the psychiatrist were scheduled. Treatment duration was
six months. More details about the intervention can be found in Van
den Brink et al. 2002 [5]. Patients in the CAU arm were free to seek
treatment outside the study protocol, which was recorded.
Baseline variables
Demographic and clinical characteristics were assessed during
hospitalization for the index-MI and obtained from medical re-
cords. Left ventricular ejection fraction (LVEF) was assessed by
echocardiography, radionuclide ventriculography, gated single pho-
ton emission computed tomography, magnetic resonance imaging or
angiography.
Endpoints
Two endpoints were evaluated: (1) a combined endpoint of car-
diovascular related hospital readmissions and cardiac mortality,
which was the primary endpoint of MIND-IT [5], and (2) all-cause
mortality. Date and cause of death and hospital readmissions was
obtained from Statistics Netherlands by linkage to the municipalpersonal records database. Considered as cardiac deaths were causes
of death with ICD-10 codes I11 (hypertensive heart disease), I20-I25
(ischemic heart diseases), I42-I50 (cardiomyopathy, conduction dis-
order, cardiac arrest, cardiac dysrhythmia, heart failure) and R57.0
(cardiogenic shock). Hospital readmissions with the following ICD-9
primary discharge diagnoses were included as cardiovascular
readmissions: ischemic heart disease (410, 411, 413, 414), cardiac
arrhythmia (427.1, 427.4, 427.5), heart failure (428, 398.91, 402.01,
402.11, 402.91, 404.01, 404.03, 404.11, 404.13, 404.91, 404.93), cere-
brovascular disease (433, 434, 435, 437.0, 437.1) and peripheral vas-
cular disease (440, 443.9).
Data on potential endpoints were gathered up to 31 December
2007. The follow-up period started at the date of randomization,
ranging between April 2000 and January 2003. Patients who did not
have the outcome of interest until 31 December 2007 were censored
on 31 December 2007 or date of death as appropriate.Statistical analyses
The initial study power calculation showed that 190 patients in
the intervention arm and 130 patients in the CAU arm were needed
to detect a reduction in the incidence of the primary outcome from
38% to 25% [5]. Because the incidence of the primary outcome up to
18 months post-MI was substantially lower than expected (13% in-
stead of 38% over a mean follow-up period of 11 months [6]), the
study power was recalculated given this event rate, a sample size of
208 and 122 patients in the intervention and CAU arm respectively,
an attrition rate of 0.1% per month, an accrual period of 33 months,
and a total follow-up period up to 93 months after the MI. This
resulted in a study power of 89% and an expected frequency of 67%
in the usual care arm versus 49% in the intervention arm for the pri-
mary outcome.
Data on the combined endpoint were present for 295 of the 330
randomized patients. To be as inclusive as possible, we included pre-
viously obtained data on the combined endpoint during the ﬁrst
18 months after MI [6] for the 35 patients with missing data on
long-term cardiac outcomes. With Cox regression, endpoints were
compared between the intervention and the CAU arm. After this,
two subgroup analyses were done. The ﬁrst subgroup analysis com-
pared endpoints between responders (i.e. ≥50% reduction in the
HDRS score or an HDRS-score of b10 after 24 weeks of treatment)
and non-responders to antidepressants. This was done as a long-
term follow-up of our previous publication, in which we reported
better 18-month cardiovascular outcomes for responders to antide-
pressants, compared to non-responders [23]. This analysis included
patients who received antidepressants only (n=70). Some patients
in the intervention arm received no treatment for depression, and
some patients in the CAU arm did. Therefore, the second subgroup
analysis compared endpoints between patients who received treat-
ment for depression and patients who did not, regardless of random-
ization status. This analysis included all patients with information on
treatment status (n=311) and was done twice: once including
patients from the nested trial receiving placebo only in the group
that received treatment, and once in the group that did not receive
treatment. This is because of the ambiguity of their treatment status,
i.e. they were randomized to the intervention, but received placebo.
In case of a statistically signiﬁcant effect on long-term cardiac
outcomes, Chi-square and t-tests were used to determine whether
subgroups differed on characteristics known to inﬂuence cardiac
outcomes. These a priori determined characteristics were age, sex,
smoking, hypertension, hypercholesterolemia, diabetes, Killip Class,
LVEF, and depression severity [1,18,19]. Then, the Cox regression
was repeated after adjustment for those characteristics that differed
substantially (pb0.10) between the groups to evaluate whether
these may explain the differential risk.
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Sample
Of 2176 eligible patients, 375 had a post-MI depressive episode, of whom 331 were
randomized. Forty-four patients were not randomized due to risk of suicide (n=28)
and end of the study (n=16, see Fig. 1). Patients in the intervention-arm did not differ
from those in the CAU arm in terms of demographics, depressive symptom severity,
cardiovascular disease severity and cardiovascular risk factors [6]. One patient who died
before the start of the intervention, was excluded from further analysis, leaving 330
patients. The combined endpoint occurred in 121 (36.7%) of the patients during a mean
follow-up of 4.0 years (standard deviation (SD) 2.5 years: range 2 days–7.7 years, total
follow-up time 1332.3 person‐years). The crude event rate was 90.8 events per 1000
person-years. All-cause mortality occurred in 46 (13.9%) of patients with a mean
follow-up of 5.2 years (SD 2.1 years, range 19 days–7.7 years, total follow-up time
1730.8 person‐years). The crude death rate was 26.6 deaths per 1000 person-years.
Effects of the intervention
Seventy-six (36.5%) of 208 patients in the intervention arm and 45 (36.9%) of 122
patients in the CAU arm had the combined endpoint of cardiovascular related hospital
readmissions and cardiac mortality (HR: 0.97 (95% CI: 0.67–1.40; p=0.850) see Fig. 2).
All-cause mortality occurred in twenty-six (12.5%) of patients in the intervention arm
versus 20 (16.4%) in the CAU arm (HR (95% CI): 0.74 (0.41–1.33) p=0.310).
Response to treatment with antidepressants
In the nested trial, 47 patients receivedmirtazapine and 44 placebo. After 8 weeks, 23
patients in the placebo group switched to citalopram, resulting in a total of 70 patients4,779 Assessed
N=331 Rand
N=209 Intervention
-N=94 Nested trial: double blind mirtazapine 
placebo1
-N=17 Open pharmacological treatment
-N=40 nonpharmacological treatment
-N=45 No treatment
-N=13 Lost (no information about treatment)
N=1 died before start of intervention
N=208 included in analysis with endpoint all -
cause mortality
N=21 no data on cardiac readmissions
N=187 included in analysis with combined end -
point of cardiac death and cardiac readmissions
Fig. 1. Flow-chart of patients in MIND-IT. 1 Of 94 patients randomized in the nested trial, 3 di
received placebo of whom 18 (41%) responded. Non-responders (20+26) were offered opreceiving antidepressants. Of these, there were 27 responders and 43 non-responders.
The combined endpoint occurred in 9 (33.3%) of 27 responders and in 16 (37.2%) of 43
non-responders (HR (95% CI) for non-responders: 1.15 (0.51–2.61) p=0.731). Three
(11.1%) of the 27 responders died versus 5 (11.6%) of the 43 non-responders (HR (95%
CI) for responders: 0.98 (0.23–4.12) p=0.976).Treatment versus no treatment for depression
Treatment status was known for 311 patients, of whom 21 received placebo only,
147 received treatment for depression (27 mirtazapine only, 20 initially mirtazapine
and later citalopram, 23 initially placebo and later citalopram, 17 open pharmacolog-
ical treatment, 40 nonpharmacological treatment, 20 of the CAU arm receiving treat-
ment) and 143 did not (45 from the intervention arm and 98 from the CAU arm, see
Fig. 1).
The combined endpoint occurred in 50 (34.0%) of 147 patients who received treat-
ment, in 55 (38.5%) of 143 patients who did not, and in 10 (47.6%) of 21 patients who
received placebo. When patients on placebo were included in the group that received
treatment, the HR (95% CI) for the combined endpoint was 0.94 (0.65–1.35; p=0.728)
for those who received treatment. When including the patients who received placebo
in the group who received no treatment this was 0.84 (0.58–1.21; p=0.340).
Fourteen (9.5%) of 147 patients who received treatment, 26 (18.2%) of 143 patients
who did not, and 2 (9.5%) of 21 patients who received placebo died. When patients on
placebo were included in the group that received treatment, the HR (95% CI) for
all-cause mortality for the group that received treatment was 0.52 (0.28–0.97; p=
0.041). When including the patients on placebo in the group who received no treat-
ment this was 0.56 (0.29–1.05; p=0.072).
Patients who received treatment (when including patients on placebo in this
group) were signiﬁcantly more likely to be men (p=0.008), and had higher for eligibility
1,403 Did not meet inclusion criteria
1,200 Refused to participate
1,801 No ICD -10 depression
28 Risk of suicide
16 Not randomized due to end of study
omized
N=122 Care as usual
-N=8 Pharmacological treatment
-N=12 nonpharmacological treatment
-N=98 no treatment
-N=4 Lost (i.e. no information about 
treatment)
N=122 included in analysis with endpoint 
all-cause mortality
N=14 no data on cardiac readmissions
N=108 included in analysis with combined end -
point of cardiac death and cardiac readmissions
d not show up, 47 received mirtazapine of whom 27 (57%) responded at week 8, and 44
en pharmacological treatment (citalopram ﬁrst choice).
Fig. 2. Kaplan Meier survival curve for cardiovascular related readmissions or cardiac
mortality after randomization associated with the intervention or CAU.
Table 2
All-cause mortality risk for 168 MI-patients who received treatment for depression
versus 143 who did not1
Adjusted for HR (95% CI)
Unadjusted 0.52 (0.28–0.97); p=0.041
Sex 0.54 (0.29–1.01); p=0.0552
BDI 3 at months post-MI 0.49 (0.26–0.93); p=0.029
Sex and BDI at 3 months post-MI 0.50 (0.26–0.96); p=0.036
BDI: Beck Depression Inventory; CI: Conﬁdence Interval; HR: Hazard Ratio; MI:
Myocardial Infarction.
1 21 patients in the intervention arm receiving placebo only were included in the
group who received treatment.
2 In this model the HR (95% CI) for mortality for men was 1.33 (0.70–2.55; p=0.383).
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not change the association between treatment status and all-cause mortality, although
after adjustment for sex alone the association lost its signiﬁcance (see Table 2).Discussion
The present paper reports the effectiveness of implementing an
antidepressant treatment strategy on cardiovascular outcomes for de-
pressed MI patients enrolled in MIND-IT. Previously, we showed in
this sample that the intervention had no effect on depression and car-
diovascular outcomes till 18 months after the MI [6]. Because poten-
tial beneﬁcial effects on cardiovascular prognosis may only appear
after a longer follow-up time, the present article presents the effects
of the intervention on cardiovascular outcomes till 8 years after treat-
ment initiation. However, the results show that the intervention did
not affect the risk of long-term cardiovascular outcomes.
Consistent with the present study, in ENRICHD CBT (which was
augmented with sertraline in MI-patients with severe depressive
symptoms and MI-patients not responding to CBT after 5 weeks)
did not reduce the risk of death or non-fatal MI up to 4 years later
[2]. In SADHART, sertraline treatment did not affect all-cause mortal-
ity rates during the 8 years following treatment initiation as well [4].
In a RCT, including 302 post-CABG patients, telephone delivered col-
laborative carewas not associatedwith a reduced risk of cardiovascularTable 1
Baseline characteristics for 168 MI patients who received treatment for depression and 143
Received tr
Age mean (SD) (n=311) 57.2 (10.5)
Male n (%) (n=311)2 135 (80.4)
Smoking n (%) (n=311) 92 (53.6)
Hypertension n (%) (n=311) 56 (33.3)
Hypercholesterolaemia n (%) (n=310) 141 (84.4)
Diabetes mellitus n (%) (n=311) 22 (13.1)
LVEFb45% n (%) (n=286) 65 (42.5)
Killip class>1 n (%) (n=310) 18 (10.7)
BDI 3 months post-MI mean (SD) (n=299)3 13.4 (6.4)
Depression severity during year following MI (n=311)
Mild n (%) 48 (28.6)
Moderate n (%) 77 (45.8)
Severe n (%) 43 (25.6)
BDI: Beck Depression Inventory; LVEF: Left Ventricular Ejection Fraction; MI: Myocardial In
1 21 patients in the intervention arm receiving placebo only were included in the group
2 p=0.008 (Chi-square).
3 p=0.054 (independent sample t-test).readmissions during the 8 month treatment period, despite a modest
effect on depression scores [20].
Lack of power may be a reason why MIND-IT's intervention did
not affect cardiovascular outcomes and mortality. The prevalence of
the primary outcome (37% in both arms) was lower than expected
based on the power calculation (49% in the intervention arm and
67% in the CAU arm). Therefore, the study power was less than the
anticipated 89% for the combined endpoint, which could explain the
null ﬁndings of the present study. After all, the HR of 0.74 for
all-cause mortality may have been statistically signiﬁcant in the pres-
ence of more power (note that the study was not powered for
all-cause mortality). Therefore, it remains unclear whether an active
antidepressant treatment strategy, such as that used in MIND-IT,
would increase survival rates in depressed MI patients. This needs
further evaluation in future studies. On the other hand, the primary
endpoint of cardiovascular readmissions and cardiac mortality oc-
curred similarly in both groups (HR 0.97). This gives not much reason
to believe that the intervention would have had a beneﬁcial effect on
the primary endpoint in the presence of more power. In addition, re-
sults from other large-scale RCTs on depression treatment in de-
pressed cardiac patients do not give support for a beneﬁcial effect of
depression treatment on cardiovascular outcomes [2–4,20]. The re-
sults of the present study do not change this view.
One potential reason why depression treatment did not affect car-
diovascular outcomes is that a more severe underlying cardiovascular
disease is driving the increased risk of new cardiovascular events in
some of the depressed patients. In the present sample, depression se-
verity was associated with cardiovascular disease severity [21], and
cardiovascular disease severity explains up to 40% of the long-term
cardiac morbidity and mortality associated with depression [22].
Therefore, the depression treatment may not have affected cardiovas-
cular outcomes because it was not the depression itself, but the moreMI patients who did not1
eatment (n=168) Received no treatment (n=143)
59.0 (11.5)
96 (67.1)
74 (51.7)
52 (36.4)
120 (83.9)
19 (13.3)
58 (43.6)
21 (14.8)
12.0 (5.4)
47 (32.9)
69 (48.3)
27 (18.9)
farction; SD: Standard Deviation.
who received treatment.
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the new events.
Although we previously reported better cardiac outcomes till
18 months after the index-MI for responders [23], treatment-response
was not associated with better long-term cardiac outcomes. A potential
reason why treatment-response was associated with short-term but
not long-term cardiac prognosis is that during the follow-up period dif-
ferences between responders and non-responders on depressive symp-
tom severity, cardiac disease severity and cardiac risk factors have
become less apparent. A potential reason why we could not replicate
ﬁndings from ENRICHD and SADHART [4,24] showing that improve-
ments in depression are associated with better long-term cardiac out-
comes, is that the size of our subgroup was smaller (27 responders
and 43 non-responders).
Better survival was found for patients who received depression
treatment compared to those who did not, which is comparable to
ﬁndings from two other studies. In ENRICHD, some patients in both
arms received (additional) treatment with antidepressants when it
was deemed necessary. While the intervention (CBT) did not reduce
the risk of poor cardiac outcomes, antidepressant use was signiﬁcantly
associated with a reduced risk of death or nonfatal recurrent MI [25].
Another study found in 93,653 depressed veterans a reduced risk of
incident MI and all-cause mortality for those who received anti-
depressant treatment [26]. The increased survival rates for patients re-
ceiving depression treatment may reﬂect a direct treatment response.
However, since these ﬁndings are all based on non-randomized com-
parisons, the association may be confounded by factors associated
with receiving treatment as well as increased survival. In MIND-IT, the
association lost its statistical signiﬁcance after adjustment for sex
(i.e. men were more likely to receive treatment and had somewhat
better survival). Surprisingly, age, cardiovascular disease severity
and risk factors known to inﬂuence cardiac prognosis were not asso-
ciated with receiving depression treatment, suggesting that whether
or not a patient received depression treatment was not depending on
his age or cardiovascular risk proﬁle. Still, one other reason why pa-
tients who received antidepressant treatment have better survival
may be the intrinsic motivation of patients to care for their health.
Patients more likely to seek treatment for depression may be more
adherent to cardiac aftercare and have a healthier lifestyle. For in-
stance, depression is found to be associated with non-adherence to
medical treatment recommendations [27], not completing and ad-
hering to cardiac rehabilitation procedures [9], and recommenda-
tions for risk factor reduction after MI [28]. Non-adherence to both
depression treatment and cardiac aftercare procedures may explain
why cardiac patients with treatment resistant depression have the
highest risk of cardiovascular morbidity and mortality [29,30].
Some limitations should be considered when interpreting the re-
sults of the present study. First, recruitment took place 10 years ago,
while in the meantime the medical management of MI and recogni-
tion of depression has changed, potentially affecting the generaliz-
ability of our ﬁndings to the current MI population. Second, the
lower prevalence of the primary outcome expected resulted in a
study power less than the anticipated 89%. A third limitation is that
we had no sufﬁcient information concerning the depression after
the treatment period for the complete sample of 330 patients. Al-
though depression was evaluated at 18 months post-MI, data were
present for only 218 (66%) patients and there may have been selec-
tive loss to follow-up (i.e. depression data may have been missing
for those with most severe depression). This is why we could not
evaluate whether patients who did not receive depression treatment
have persisting depression, or whether persisting or treatment-
resistant depression was associated with cardiovascular morbidity
and mortality in the complete sample of 330 patients. Fourth, it
should be considered that MIND-IT's intervention was complex.
Patients received different types and intensities of treatment, and
for some patients the type and intensity of the depression treatmentwere not known (i.e. those in the intervention arm who received
tailored treatment and those in the CAU arm who received treatment
from their own physicians). Therefore, it is difﬁcult to judge the ade-
quacy of treatment in many patients.
Taken together, our results suggest that the implementation of an
antidepressant treatment strategy in depressed MI-patients does not
affect long-term cardiovascular outcomes. Although patients receiv-
ing treatment for depression had better survival rates, it remains
unclear whether this is due to the treatment itself or is due to
unmeasured factors that relate to both receiving depression treat-
ment and mortality.
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